Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016

Quarterly and Year-to-Date Net Revenue Increase 18.0% and 105.8% When
Compared to 2016

FlutiCare™ Launches on November 14, 2017

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”)
(OTCQB: INNV) today announced third quarter 2017 net revenue of $2.2
million compared to $1.9 million in net revenue for the same period in
2016. Net revenue for the nine months ended September 30, 2017 was $6.4
million compared to $3.1 million for the same period in 2016.

“We have increased our year-to-date product sales by over 105% when
compared to the prior year without the potential added sales of
FlutiCare™. This demonstrates our continued ability to generate
significant sales growth from new and existing products through our
Beyond Human® Sales and Marketing Platform,” stated Bassam Damaj,
President and Chief Executive Officer of Innovus Pharma. “Our first
commercial batch of FlutiCare™ was received in October and we launched
FlutiCare™ today which is one of the largest milestones for the Company.
With the launch, we expect to continue the trend of increasing our net
revenue while decreasing our loss from operations as we work towards our
goal of profitability in 2018,” continued Dr. Damaj.

Financial highlights for the three months ended September 30, 2017
included:

  • Net revenue totaled $2.2 million for the three months ended September
    30, 2017, compared to net revenue of $1.9 million for the three months
    ended September 30, 2016.
  • Net revenue during the third quarter of 2017 was impacted by the
    natural disasters in Florida and Texas as the Company was unable to
    advertise its products for a period of time in those regions as a
    result. These two states generate close to 15% of our total net
    revenue and have a population of approximately 17 million in our
    targeted product demographics*.
  • Total operating expense was $3.4 million for the three months ended
    September 30, 2017 or year over year decrease of $0.7 million or 16.7%
    when compared to the three months ended September 30, 2016.
  • Loss from operations decreased by $1.0 million or 45.8% to $1.2
    million for the three months ended September 30, 2017 compared to the
    three months ended September 30, 2016.
  • Net loss totaled $1.3 million, or ($0.01) per common share, for the
    three months ended September 30, 2017 representing a 70.0% decrease
    year over year. The net loss included $0.5 million in non-cash expense
    related to the amortization of debt discounts, stock-based
    compensation and depreciation and amortization. Net loss for the three
    months ended September 30, 2016 totaled $4.4 million or ($0.04) per
    common share.
  • Cash used in operations decreased to approximately $577,000 for the
    three months ended September 30, 2017 compared to approximately
    $996,000 for the three months ended September 30, 2016.
  • Cash balance totaled $1.3 million at September 30, 2017.

Financial highlights for the nine months ended September 30, 2017
included:

  • Net revenue increased 105.8% to $6.4 million for the nine months ended
    September 30, 2017, compared to net revenue of $3.1 million for the
    nine months ended September 30, 2016.
  • Gross margin increased to 79.4% for the nine months ended September
    30, 2017, higher than gross margin for the nine months ended September
    30, 2016 which totaled 77.2%.
  • Total operating expense increased to $10.4 million and included $1.0
    million in non-cash share-based compensation and $0.5 million in
    non-cash depreciation and amortization for the nine months ended
    September 30, 2017.
  • Net loss totaled $5.0 million, or ($0.03) per common share, for the
    nine months ended September 30, 2017. The net loss included a non-cash
    expense of $0.4 million for the loss on extinguishment of debt as a
    result of the prepayment of the remaining 2016 convertible debentures
    and settlement of notes payable. The net loss also included interest
    expense of $0.8 million, of which $0.7 million was non-cash and
    related to the amortization of debt discounts. Net loss for the nine
    months ended September 30, 2016 totaled $10.3 million or ($0.12) per
    common share.

Third quarter 2017 and recent developments:

  • Received our first commercial batch of 220,000 units of FlutiCare™ in
    October and launched FlutiCare™ in the U.S. in November 2017;
  • Moved corporate and company operations into a new 17,000 square-foot
    facility in San Diego, CA in November 2017 that will bring in-house
    the Company’s product fulfillment and inventory storage process. The
    move is designed to lower product fulfillment costs which will
    increase our gross product margins and decrease our loss from
    operations, as well as, provide the necessary office space to
    accommodate our expected revenue growth in 2018;
  • The combination of Apeaz™ cream for arthritis pain relief and
    ArthriVarx™, a supplement designed to maximize and support joint
    health, launched under the Beyond Human® Sales and Marketing Platform
    in July 2017;
  • Entered into an agreement with ACON Laboratories, Inc. to offer
    our customers a new FDA cleared urinary tract infection test in
    combination with their purchase of UriVarx™ and an FDA cleared glucose
    monitoring meter and test strips called the GlucoGorx™ Kit with their
    purchase of GlucoGorx™, the Company’s upcoming supplement for diabetic
    patients;
  • Received approval as a Natural Health Product by Health Canada for
    UriVarx™ for the indication to reduce symptoms of overactive bladder
    in September 2017 and for Vesele® to help improve nitric oxide
    production in symptoms of sexual dysfunction in October 2017;
  • Continued expansion of patent portfolio by receiving first
    Notification to Grant a Patent Right for Sensum+® in China in October
    2017. Innovus Pharma has currently fourteen (14) issued patents and
    eight (8) patent applications covering several of its products and has
    licensed in an additional four (4) patents and five (5) patent
    applications from third parties covering additional products;
  • Expanded the exclusive license and distribution territory under our
    agreement with Densmore to Singapore and Vietnam in July 2017; and
  • Approval notification as a Class I medical device was received to
    commercialize Zestra® in Australia in July 2017 and in New Zealand in
    September 2017.

The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT
today to discuss the financial results and recent business developments.
To participate in the call, please dial 1-877-883-0383 for domestic
callers or 1-412-902-6506 for international callers. Participant Elite
Entry Number: 5606897. A replay of the call will be available for 30
days. To access the replay, dial 1-877-344-7529 domestically or
1-412-317-0088 internationally and reference Conference ID: 10113950.
The replay will be available shortly after the end of the conference
call.

   

Consolidated Statements of Operations

(Unaudited)

For the

Three Months Ended

September 30,

2017

       

2016

 
Net revenue:
Product sales, net $ 2,218,343 $ 1,882,129
License revenue   2,500      
Net revenue   2,220,843     1,882,129  
 
Operating expense:
Cost of product sales 480,076 331,227
Research and development 8,736 43,775
Sales and marketing 1,626,630 1,972,155
General and administrative   1,321,001     1,779,048  
Total operating expense   3,436,443     4,126,205  
 
Loss from operations   (1,215,600 )   (2,244,076 )
 
Other income and (expense):
Interest expense (104,276 ) (3,719,200 )
Loss on extinguishment of debt (89,341 )
Other income (expense), net (4,800 ) (37 )
Fair value adjustment for contingent consideration 69,305 186,813
Change in fair value of derivative liabilities   16,055     1,350,688  
Total other expense, net   (113,057 )   (2,181,736 )
 
Loss before provision for income taxes (1,328,657 ) (4,425,812 )
 
Provision for income taxes        
 
Net loss $ (1,328,657 ) $ (4,425,812 )
 
Net loss per share of common stock – basic and diluted $ (0.01 ) $ (0.04 )
 
Weighted average number of shares of common stock outstanding –
basic and diluted
  161,587,934       104,972,645  

 

 

 
 
 
(Unaudited)

For the

Nine Months Ended
September 30,
2017   2016  
Net revenue:
Product sales, net $ 6,426,790 $ 3,126,112
License revenue   10,000     1,000  
Net revenue   6,436,790     3,127,112  
 
Operating expense:
Cost of product sales 1,329,131 714,284
Research and development 26,982 47,667
Sales and marketing 4,869,717 2,257,166
General and administrative   4,207,899     4,012,357  
Total operating expense   10,433,729     7,031,474  
 
Loss from operations   (3,996,939 )   (3,904,362 )
 
Other income and (expense):
Interest expense (771,885 ) (5,970,450 )
Loss on extinguishment of debt (394,169 )
Other income (expense), net (5,622 ) 1,839
Fair value adjustment for contingent consideration 195,459 164,479
Change in fair value of derivative liabilities   (32,138 )   (632,627 )
 
Total other expense, net   (1,008,355 )   (6,436,759 )
 
Loss before provision for income taxes (5,005,294 ) (10,341,121 )
 
Provision for income taxes   3,200      
 
Net loss $ (5,008,494 ) $ (10,341,121 )
 
Net loss per share of common stock – basic and diluted $ (0.03 ) $ (0.12 )
 
Weighted average number of shares of common stock outstanding –
basic and diluted
  152,325,196       86,498,234  
 
 
       

Condensed Consolidated Balance Sheet Data

September 30, December 31,
2017 2016
(Unaudited) (1)
Assets
Cash $ 1,315,059 $ 829,933
Accounts receivable, net 27,526 33,575
Prepaid expense and other current assets 265,217 863,664
Inventories 640,055 599,856
Intangible assets & other non-current assets   5,429,548   5,900,350
Total assets $ 7,677,405 $ 8,227,378
 
Liabilities & Stockholders’ Equity
Accounts payable and accrued expense $ 1,356,057 $ 1,210,050
Total accrued compensation 2,733,091 2,299,593
Deferred revenue and customer deposits 11,000
Accrued interest payable 21,353 47,782
Total notes payable and non-convertible debenture, net of discount 780,056 681,127
Total derivative liabilities 74,151 483,744
Total contingent consideration 1,490,458 1,685,917
Convertible debentures, net of discount 714,192
Total stockholders’ equity   1,222,239   1,093,973
Total liabilities and stockholders’ equity $ 7,677,405 $ 8,227,378
 

(1) The Condensed Consolidated Balance Sheet Data has been
derived from the audited consolidated financial statements as of
that date.

 

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men’s
and women’s health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly, (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists, and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to be a leader in developing and marketing new OTC and branded
Abbreviated New Drug Application (“ANDA”) products, men’s and women’s
health supplements, related diagnostics and medical devices. The Company
is actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx) to
OTC, as well as related products.

For more information, go to www.innovuspharma.com;
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.urivarx.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com;
www.prostagorx.com;
www.fluticare.com;
www.allervarx.com;
and www.apeaz.com.

* Population data for Florida and Texas gathered from the 2010 Census
Brief from the United States Census Bureau.

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, its financial results, projected revenues, projected online
subscribers and other customers, estimated markets for its products, and
statements about achieving its other corporate and business development,
growth, commercialization, financial and staffing objectives. Readers
are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC’s website or without charge from the Company.

Contacts

Emerging Markets Consulting, LLC
James S. Painter, III, (407)
340-0226
jamespainter@emergingmarketsllc.com